Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemab Therapeutics HoldingsCOAG +3.48%11 Forward Dividend Yield % is 0.00% as of Aug. 04, 2026. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 149 Biotechnology companies, Hemab Therapeutics Holdings ranks worse than 671140.27% on this metric.
COAG's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.35 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Hemab Therapeutics Holdings Forward Dividend Yield % Related Terms
COAG vs ZLAB, SLS, IOVA: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Hemab Therapeutics Holdings (COAG) has a Forward Dividend Yield % of 0.00% as of Aug. 04, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Hemab Therapeutics Holdings and its competitors. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 149 companies in the Biotechnology industry.
Is Hemab Therapeutics Holdings' Forward Dividend Yield % too high?
Hemab Therapeutics Holdings' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Forward Dividend Yield % compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Hemab Therapeutics Holdings in the lower half of its industry. The industry median Forward Dividend Yield % is 1.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.35, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Hemab Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Forward Dividend Yield % is 0.00% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score
Get the complete analysis for COAG
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
